1
|
Berryhill S, Morton CJ, Dean A, Berryhill A, Provencio-Dean N, Patel SI, Estep L, Combs D, Mashaqi S, Gerald LB, Krishnan J, Parthasarathy S. 1209 Effect Of Wearables On Sleep In Healthy Individuals: A Randomized Cross-over Trial And Validation Study. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.1203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
To determine whether a wearable sleep-tracker improves perceived sleep quality in healthy subjects. To test whether wearables reliably measure sleep quantity and quality compared to polysomnography.
Methods
A single-center randomized cross-over trial of community-based participants without medical conditions or sleep disorders. Wearable device (WHOOP, Inc.) that provided feedback regarding sleep information to the participant for 1-week and maintaining sleep logs versus 1-week of maintaining sleep logs alone. Self-reported daily sleep behaviors were documented in sleep logs. Polysomnography was performed on one night when wearing the wearable. PROMIS Sleep disturbance sleep scale was measured at baseline, 7, and 14 days of study participation.
Results
In 32 participants (21 women; 23.8 + 5 years), wearables improved nighttime sleep quality (PROMIS sleep disturbance; B= -1.69; 95% Confidence Interval -3.11, -0.27; P=0.021) after adjusting for age, sex, baseline, and order effect. There was a small increase in self-reported daytime naps when wearing the device (B = 3.2; SE 1.4; P=0.023) but total daily sleep remained unchanged (P=0.43). The wearable had low bias (2.5 minutes) and low precision (5.6 minutes) errors for measuring sleep duration and measured dream sleep and slow wave sleep accurately (Intra-class coefficient 0.74 + 0.28 and 0.85 + 0.15, respectively). Bias and precision error for heart rate (bias -0.17%; precision 1.5%) and respiratory rate (bias 1.8%’ precision 6.7%) were very low when compared to that measured by electrocardiogram and inductance plethysmography during polysomnography.
Conclusion
In healthy people, wearables can improve sleep quality and accurately measure sleep and cardiorespiratory variables.
Support
WHOOP Inc.
Collapse
Affiliation(s)
- S Berryhill
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - C J Morton
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - A Dean
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - A Berryhill
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - N Provencio-Dean
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - S I Patel
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - L Estep
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - D Combs
- Department of Pediatrics, University of Arizona, Tucson, AZ
| | - S Mashaqi
- UAHS Center for Sleep & Circadian Sciences; Division of Pulmonary, Allergy, Critical Care & Sleep Medicine; University of Arizona, University of Arizona, AZ
| | - L B Gerald
- Asthma and Airways Disease Research Center, Tucson, AZ
| | - J Krishnan
- Breathe Chicago Center and Division of Pulmonary, Critical Care, Sleep, & Allergy, University of Illinois, Chicago, Illinois, Chicago, IL
| | - S Parthasarathy
- University of Arizona Health Sciences Center for Sleep and Circadian Sciences, University of Arizona, AZ
| |
Collapse
|
2
|
Berryhill A, Bhamre S, Chaudhuri A, Concepcion W, Grimm PC. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period. Pediatr Transplant 2016; 20:141-5. [PMID: 26477696 DOI: 10.1111/petr.12617] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/02/2015] [Indexed: 11/27/2022]
Abstract
Nephropathic cystinosis is a rare disorder causing the accumulation of intracellular cystine crystals in tissues. The damage to the proximal tubules of the kidneys results in Fanconi syndrome, and patients with cystinosis experience the progression of chronic kidney disease, resulting in the need for kidney transplantation. Treatment of cystinosis with cysteamine has proven to be effective; however, it has many gastrointestinal side effects that are concerning for transplant specialists during the immediate post-transplant period. Transplant specialists routinely discontinue cysteamine therapy for up to six weeks to ensure proper immunosuppressant absorption. This practice is worrisome because it communicates the acceptability of lapses of cysteamine treatment to patients. It may be better to re-initiate cysteamine therapy shortly after transplantation while the patient is followed more closely by the transplant team. This report presents two pediatric patients with nephropathic cystinosis who successfully restarted cysteamine therapy in the immediate post-transplant period without issue in regard to immunosuppression absorption or gastrointestinal side effects. These cases challenge current practice of discontinuing cysteamine therapy during kidney transplantation, and immediate re-initiation of cysteamine therapy in cystinosis patients post-transplant should be considered.
Collapse
Affiliation(s)
- Allison Berryhill
- Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, USA
| | - Suvarna Bhamre
- School of Medicine, Stanford University, Palo Alto, CA, USA
| | | | | | - Paul C Grimm
- School of Medicine, Stanford University, Palo Alto, CA, USA
| |
Collapse
|